-
公开(公告)号：EP1800689A1
公开(公告)日：2007-06-27
申请号：EP05774895.6
申请日：2005-08-24
IPC分类号： A61K38/04 , A61K9/08 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/14 , A61K47/16 , A61K47/20 , A61K47/22 , A61K47/26 , A61K47/40 , A61P5/00
摘要： An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.
-
公开(公告)号：EP0794256B1
公开(公告)日：2006-02-08
申请号：EP97301428.5
申请日：1997-03-04
发明人： Magota, Koji , Rogi, Tomohiro , Sakai, Yasuyoshi , Kato, Nobuo
CPC分类号： C12N9/60 , C12N15/815
-
公开(公告)号：EP1142586B1
公开(公告)日：2007-04-25
申请号：EP00971729.9
申请日：2000-11-01
发明人： FUKAMI, Harukazu , URATA, Hidenori
IPC分类号： A61K31/517 , A61P9/10
CPC分类号： A61K31/517 , C07D239/96
摘要： Preventive or therapeutic agents for diseases accompanied with vascular function disorders related to deposition of lipid on vessel walls, containing specific chymase inhibitors as the active ingredient. Quinazoline derivatives of general formula (1) are usable as the specific chymase inhibitor. In said formula, A is an aromatic ring.
-
4.发明授权PREVENTIVES OR REMEDIES FOR DISEASES INDUCED BY HYPOFUNCTION OF NITRIC OXIDE SYNTHASE (NOS) 失效造成的氮氧化氮合酶LACK（NOS）用于疾病的预防或治疗剂跳闸ARE
公开(公告)号：EP0908182B2
公开(公告)日：2007-03-28
申请号：EP97937845.2
申请日：1997-08-29
发明人： ISHIHARA, Takafumi , KANAYAMA, Yoshiharu , OKAMURA, Mikio , YOSHIKAWA, Junichi , SHINTAKU, Haruo
IPC分类号： A61K31/505 , A61P37/00 , A61P25/00 , A61P9/00 , A61P1/00
CPC分类号： A61K31/525 , A61K31/519 , C07D475/04
摘要： Remedies containing as the active ingredient compounds represented by general formula (I) or pharmaceutically acceptable salts thereof, whereby diseases induced by the hypofunction of NOS can be efficaciously prevented or ameliorated, wherein R?1 and R2¿ represent each hydrogen, or R?1 and R2¿ form together a single bond; and R3 represents -CH(OH)CH(OH)CH¿3?, CH(OCOCH3)CH(OCOCH3)CH3, -CH3, -CH2OH or phenyl when R?1 and R2¿ are hydrogen, or R3 represents -COCH(OH)CH¿3? when R?1 and R2¿ form together a single bond.
-
5.发明公开METHOD OF PROLIFERATING PLURIPOTENT STEM CELL 有权VERFAHREN ZUR PROLIFEATION EINER PLURPOTENTEN STAMMZELLE
公开(公告)号：EP1734112A1
公开(公告)日：2006-12-20
申请号：EP05727500.0
申请日：2005-03-23
CPC分类号： C12N5/0606 , C12N2533/50
摘要： A novel growth method is provided for pluripotent stem cells such as ES cells. The method of the invention is a pluripotent stem cell growing method and gene transfer method in which pluripotent stem cells are cultured under conditions that maintain their undifferentiated state and pluripotency, the method being characterized by using a liquid medium and a culturing vessel having immobilized or coated on a substrate solid phase surface a molecule which is adhesive to the pluripotent stem cells in a fixed concentration, to grow the pluripotent stem cells in a dispersed state while maintaining their undifferentiated state and pluripotency, without using feeder cells, or to transfer and express a gene therein.
摘要翻译： 为多能干细胞如ES细胞提供了一种新的生长方法。 本发明的方法是多能干细胞生长方法和基因转移方法，其中多能干细胞在保持其未分化状态和多能性的条件下培养，该方法的特征在于使用液体培养基和具有固定或涂覆的培养容器 在底物固相表面上以固定浓度与多能干细胞粘合的分子，以分散状态生长多能干细胞，同时保持其未分化状态和多能性，而不使用饲养细胞，或转移和表达 基因。
-
6.发明公开SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-KAPPA B INHIBITING ACTIVITY 审中-公开与NF-KAPPA-B锁效应取代苯甲酸
公开(公告)号：EP1437339A4
公开(公告)日：2006-10-04
申请号：EP02765501
申请日：2002-09-11
发明人： SUZUKI KENJI , NUNOKAWA YOICHI
IPC分类号： A61K31/167 , A61K31/192 , A61K31/235 , A61K31/4409 , A61K31/4418 , A61K31/4453 , A61K31/4545 , A61K31/5375 , A61K31/5377 , A61P1/00 , A61P1/16 , A61P3/10 , A61P9/10 , A61P19/02 , A61P29/00 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/02 , A61P37/02 , A61P43/00 , C07C65/24 , C07C66/00 , C07C69/94 , C07C235/84 , C07D213/55 , C07D213/56 , C07D295/192 , C07D295/18
CPC分类号： C07D295/192 , A61K31/167 , A61K31/192 , A61K31/235 , A61K31/4409 , A61K31/4418 , A61K31/4453 , A61K31/4545 , A61K31/5375 , A61K31/5377 , C07C65/24 , C07C66/00 , C07C69/94 , C07C235/84 , C07D213/55 , C07D213/56
摘要： A substituted benzoic acid derivative which is represented by the following formula (I) and has an NF-kappaB inhibiting action (in the formula, R 3 , R 4 and R 5 each independently represents a hydrogen atom, an alkyl group having 1 to 6 carbon(s) or an alkoxy group having 1 to 6 carbon(s); R 9 and R 10 each independently represents a hydrogen atom, an alkyl group having 1 to 6 carbon(s) or an acyl group having 2 to 11 carbons); R 2 represents an optionally-substituted aromatic hydrocarbon group or an optionally-substituted heterocyclic group; and X represents a carboxyl group which may be esterified or amidated)
-
公开(公告)号：EP1693451A1
公开(公告)日：2006-08-23
申请号：EP04818986.4
申请日：2004-11-19
IPC分类号： C12N15/09 , C12N5/10 , A61K31/7088 , A61K35/34 , A61K35/76 , A61K48/00 , A61P9/00 , A61P9/04 , A61P9/10
CPC分类号： C12N5/0657 , A61K31/7088 , A61K35/12 , A61K48/00 , C07K14/4738 , C12N9/1205 , C12N2510/00
摘要： The proliferation of cardiomyocytes is induced by expressing cyclin and CDK in the cardiomyocytes, and by suppressing the function or action of a Cip/Kip family protein or inhibiting the production of a Cip/Kip family protein. Among the Cip/Kip family proteins, it is preferable to suppress the function of p27 Kip1 or inhibiting the production thereof. As a recombinant vector to be used therefor, there is provided a vector comprising: (1) a cyclin gene; (2) a cyclin-dependent kinase gene; and (3) one or a plurality selected from the group consisting of a gene encoding a factor that inhibits the function or action of a Cip/Kip family protein and a nucleic acid sequence that inhibits the production of Cip/Kip family protein.
摘要翻译： 通过在心肌细胞中表达细胞周期蛋白和CDK，抑制Cip / Kip家族蛋白的功能或作用或抑制Cip / Kip家族蛋白的产生来诱导心肌细胞的增殖。 在Cip / Kip族蛋白质中，优选抑制p27 Kip1的功能或抑制其生产。 作为用于其的重组载体，提供了载体，其包含：（1）细胞周期蛋白基因; （2）细胞周期蛋白依赖性激酶基因; 和（3）选自由编码抑制Cip / Kip家族蛋白的功能或作用的因子的基因和抑制Cip / Kip家族蛋白的产生的核酸序列组成的组中的一种或多种。
-
公开(公告)号：EP1114035B1
公开(公告)日：2006-05-17
申请号：EP99938565.1
申请日：1999-08-20
发明人： FUKAMI, Harukazu , ITO, Akiko , IMAJO, Seiichi
IPC分类号： C07D239/96 , C07D403/12 , C07D413/12 , A61K31/505 , A61P9/10 , A61P11/06 , A61P37/08
CPC分类号： C07D401/12 , C07C311/60 , C07D239/96 , C07D413/12
摘要： A quinazoline derivative having formula (I), or a pharmaceutically acceptable salt thereof, which has a chymase inhibitory activity and suppresses the exacerbation of vascular permeability induced by chymase and useful as a medicament, and a pharmaceutical composition containing the same as an essential ingredient.
-
公开(公告)号：EP1466610A4
公开(公告)日：2007-03-21
申请号：EP02783628
申请日：2002-11-26
IPC分类号： A61K38/00 , A61K9/00 , A61K38/22 , A61K38/26 , A61K38/28 , A61K47/02 , A61K47/46 , A61K9/14 , A61K47/12 , A61K47/34 , A61K47/36 , A61K47/38
CPC分类号： A61K9/0043 , A61K38/2278 , A61K38/26 , A61K38/28 , A61K47/02 , A61K47/46
摘要： A pharmaceutical composition for nasal administration exhibits an improved bioavailability of a biologically active polypeptide, the active ingredient of the pharmaceutical composition. Specifically, the composition is prepared by uniformly dispersing and embedding a biologically active acidic polypeptide having an isoelectric point of 7 or lower on the surfaces of a polyvalent metal compound carrier with the help of an additive capable of dispersing and embedding the polypeptide on the surfaces of the carrier. The polyvalent metal compound carrier is a metal compound with a valent of 2 or higher that is either insoluble or little soluble in water, examples being aluminum compounds, calcium compounds, magnesium compounds, silicone compounds, iron compounds, and zinc compounds.
-
10.发明授权THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT 有权按用途分的抑制剂作为活性成分糜酶嗜酸细胞治疗
公开(公告)号：EP1174151B1
公开(公告)日：2007-01-24
申请号：EP01906225.6
申请日：2001-02-22
IPC分类号： A61K45/00 , A61K31/517 , A61K31/536 , A61P43/00 , A61P37/08 , A61P11/06 , A61P27/16 , A61P27/14 , A61P17/04 , C07D239/96
CPC分类号： C07D239/96 , A61K31/00 , A61K31/517 , A61K31/536
摘要： Preventive or therapeutic drugs, which inhibit the progression of eosinophilia-related diseases while preventing the progression of various complications, and are so safe by virtue of their being free from adverse effects as to bring about enhancement in the quality of daily life of a patient. Specifically, preventive or therapeutic drugs for eosinophilia-related diseases containing chymase inhibitors as the active ingredient, wherein the chymase inhibitors are quinazoline derivatives of the general formula (I) or pharmacologically acceptable salts thereof: (I)
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.018 秒)
